RecruitingPhase 2Phase 3NCT07010159

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis

A Phase 2/3 Efficacy and Safety Study of KPL-387 Treatment in Participants With Recurrent Pericarditis

Sponsor

Kiniksa Pharmaceuticals International, plc

Enrollment

165 participants

Start Date

Jul 25, 2025

Study Type

INTERVENTIONAL

Conditions

Pericarditis Recurrent Pericarditis Pericarditis Acute

Summary

This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called KPL-387 and a drug called Placebo for people with pericarditis, pericarditis acute, and other related conditions. The study is currently recruiting participants at 58 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGKPL-387

administered by subcutaneous injection

DRUGPlacebo

administered by subcutaneous injection

Locations(58)

Investigational Site 018

Gilbert, Arizona, United States

Investigational Site 053

Phoenix, Arizona, United States

Investigational Site 030

Los Angeles, California, United States

Investigational Site 008

San Francisco, California, United States

Investigational Site 044

Santa Monica, California, United States

Investigational Site 058

Ventura, California, United States

Investigational Site 016

Westminster, Colorado, United States

Investigational Site 001

Columbus, Georgia, United States

Investigational Site 004

Chicago, Illinois, United States

Investigational Site 014

Indianapolis, Indiana, United States

Investigational Site 002

Overland Park, Kansas, United States

Investigational Site 043

Baltimore, Maryland, United States

Investigational Site 054

Boston, Massachusetts, United States

Investigational Site 055

Minneapolis, Minnesota, United States

Investigational Site 012

Rochester, Minnesota, United States

Investigational Site 050

Kansas City, Missouri, United States

Investigational Site 046

Kansas City, Missouri, United States

Investigational Site 015

New York, New York, United States

Investigational Site 022

New York, New York, United States

Investigational Site 009

Cincinnati, Ohio, United States

Investigational Site 003

Cleveland, Ohio, United States

Investigational Site 005

Austin, Texas, United States

Investigational Site 013

Houston, Texas, United States

Investigational Site 042

Burlington, Vermont, United States

Investigational Site 006

Charlottesville, Virginia, United States

Investigational Site 023

Norfolk, Virginia, United States

Investigational Site 045

Richmond, Virginia, United States

Investigational Site 027

Ottawa, Ontario, Canada

Investigational Site 028

Montpellier, France

Investigational Site 021

Paris, France

Investigational Site 036

Pessac, France

Investigational Site 019

Poitiers, France

Investigational Site 037

Toulouse, France

Investigational Site 038

Toulouse, France

Investigational Site 052

Dresden, Germany

Investigational Site 034

Athens, Greece

Investigational Site 039

Nea Ionia, Greece

Investigational Site 032

Voula, Greece

Investigational Site 029

Genoa, Italy

Investigational Site 040

Genoa, Italy

Investigational Site 056

Milan, Italy

Investigational Site 007

Milan, Italy

Investigational Site 050

Padua, Italy

Investigational Site 033

Udine, Italy

Investigational Site 041

Varese, Italy

Investigational Site 051

Warsaw, Poland

Investigational Site 031

Warsaw, Poland

Investigational Site 025

Belgrade, Serbia

Investigational Site 026

Belgrade, Serbia

Investigational Site 048

Barcelona, Spain

Investigational Site 010

Barcelona, Spain

Investigational Site 024

Madrid, Spain

Investigational Site 011

Murcia, Spain

Investigational Site 057

Valencia, Spain

Investigational Site 020

London, United Kingdom

Investigational Site 047

London, United Kingdom

Investigational Site 035

London, United Kingdom

Investigational Site 017

Southampton, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07010159

Related Trials

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

NCT0670829927 locations

Transition to KPL-387 Monotherapy Dosing & Administration Study

NCT0728821639 locations

EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases

NCT070773041 location

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

NCT0683623218 locations

CACP: Study on Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome

NCT0746846110 locations